Zecotek Photonics' proprietary TGFL selected for research in flow cytometry

Zecotek Photonics Inc. (TSX VENTURE:ZMS)(FRANKFURT:W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the National Cancer Institute, a division of the U.S. National Institutes of Health (NIH), has selected its proprietary Tunable Green Fiber Laser (TGFL) for research in flow cytometry. The TGFL is the world's first tunable fiber laser emitting in the visible wavelength range. This latest order follows the purchase by the National Cancer Institute of Zecotek's Fixed Wavelength Green Fiber Laser (FGFL), for cytometric research. Dr. William Telford, Head of the Flow Cytometry Core Laboratory at the National Cancer Institute/NIH is leading the experimental work to be conducted with this laser.

"The wavelength range that Zecotek's Tunable Green Fiber Laser provides is ideal for our research which is aimed at discovering new fluorescent probes for application in immunology, hematology, organ transplantation and biomedical research," said Dr. Telford.

"We are very gratified the National Cancer Institute has selected our Tunable Green Fiber Laser for an area of research that directly contributes to advancements in bio-instrumentation," said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek. "Dr. Telford's research is closely followed by industry and his results have contributed to the strong interest from bio-instrumentation OEMs in our FGFL and TGFL for flow cytometry and other systems which, we anticipate, will contribute to strong sales growth in early 2010."

Under an extension of the joint manufacturing agreement with Fujikura, the FGFL and TGFL series will carry the Zecotek label in North America, with manufacturing and manufacturer's warranty remaining with Fujikura of Japan.